Lifeward Ltd. (LFWD) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights operational efficiencies and a strong pipeline, but concerns arise due to increased operating expenses and cash constraints. The Q&A reveals optimism in partnerships and revenue growth, yet lacks clarity on strategic execution. Despite the positive outlook, uncertainties in Medicare reliance and AlterG sales decline temper enthusiasm. The neutral rating reflects mixed signals, with potential growth balanced by financial and operational challenges.
Key Financial Performance
Revenue Lifeward's reported revenue of $6.2 million in Q3 2025 compared to $6.1 million in Q3 2024, an increase of $0.1 million or approximately 1.1%. The increase was driven primarily by higher Medicare unit sales in the U.S.
Revenue from traditional products and services Revenue totaled $3.1 million in Q3 2025 compared to $2.5 million in Q3 2024, an increase of $600,000 or 24%. This increase was driven by year-over-year increase in Medicare-related sales.
Revenue from AlterG products and services Revenue was $3.1 million in Q3 2025, down from $3.6 million in Q3 2024. The decrease was primarily driven by timing factors and quarterly revenue mix.
Gross Profit (GAAP) Gross profit was $2.7 million or 43.7% of revenue in Q3 2025 compared to $2.2 million or 36.2% of revenue in Q3 2024. The increase was primarily driven by lower production costs following the December 2024 closure of the Fremont, California manufacturing facility.
Gross Profit (Non-GAAP) Gross profit was $2.7 million or 43.7% of revenue in Q3 2025 compared to $2.6 million or 42.5% of revenue in Q3 2024. The increase was primarily driven by lower production costs following the December 2024 closure of the Fremont, California manufacturing facility.
Operating Expenses (GAAP) Operating expenses were $5.9 million in Q3 2025 compared to $5.4 million in Q3 2024. The increase was largely driven by a $2 million earn-out write-down recognized in the prior year quarter.
Operating Expenses (Non-GAAP) Adjusted operating expenses were $5.7 million in Q3 2025 compared to $6.7 million in Q3 2024. The decrease primarily reflects greater efficiency in reimbursement activities, improved efficiencies in marketing and sales operations, and lower R&D spending after the completion of major development programs.
Operating Loss (GAAP) Operating loss was $3.1 million in Q3 2025 compared to $3.2 million in Q3 2024. The slight improvement reflects operational efficiencies.
Operating Loss (Non-GAAP) Operating loss was $3 million in Q3 2025 compared to $4.1 million in Q3 2024. The improvement reflects operational efficiencies and cost management initiatives.
Cash and Cash Equivalents Ended Q3 2025 with $2 million in cash and cash equivalents, including $1.2 million raised through the ATM facility. This reflects improved operational efficiencies and the consolidation of manufacturing facilities.
Operating Cash Usage Operating cash usage was $3.8 million in Q3 2025 compared to $4.5 million in Q3 2024. The improvement reflects the benefits of operational efficiencies and the consolidation of manufacturing facilities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ReWalk 7 Personal Exoskeleton: Achieved record placements for Medicare beneficiaries for the second consecutive quarter. Received first Medicare Advantage commercial revenue for this product.
MyoCycle FES bike and ReStore Exo-suit: Revenue from these products contributed to a 24% year-over-year increase in revenue for traditional products and services.
European Market Expansion: CE mark approval expanded access to the European market, representing 40% of the global addressable exoskeleton opportunity.
Operational Efficiencies: Achieved a 16% reduction in quarterly cash burn and a 27% reduction in non-GAAP operating loss compared to last year. Improved efficiencies in reimbursement, marketing, and sales operations.
Manufacturing Consolidation: Lower production costs due to the closure of the Fremont, California manufacturing facility in December 2024.
Strategic Rebuild: Focused on rebuilding fundamentals, improving operational discipline, and aligning the organization around a scalable, data-driven approach.
Financial Position Enhancement: Secured a $3 million loan from Oramed to enhance liquidity and support the transformation plan.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Liquidity and Financial Stability: The company has $2 million in cash and cash equivalents, which is only sufficient to fund operations into the first quarter of 2026. This creates a risk of liquidity constraints if additional funding is not secured.
Revenue Growth Challenges: Revenue growth is modest, with only a 1.1% year-over-year increase in Q3 2025. This slow growth could hinder the company's ability to scale and meet strategic objectives.
Dependence on Medicare Sales: A significant portion of revenue growth is driven by Medicare-related sales. Any changes in Medicare policies or reimbursement rates could adversely impact revenue.
Operational Efficiency Risks: While operational efficiencies have been implemented, the company is still in the early stages of a multi-quarter rebuild. There is a risk that these measures may not yield the expected long-term benefits.
Product Line Revenue Decline: Revenue from the AlterG product line decreased from $3.6 million in Q3 2024 to $3.1 million in Q3 2025, indicating potential challenges in maintaining demand for this product line.
Manufacturing Consolidation Risks: The closure of the Fremont, California manufacturing facility has reduced production costs, but it may also pose risks related to supply chain disruptions or production capacity.
Debt and Financial Obligations: The company recently entered into a $3 million loan agreement, which adds financial obligations and could impact future cash flow.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Lifeward reaffirms its full-year 2025 revenue guidance, expecting revenue in the range of $24 million to $26 million.
Non-GAAP Net Loss Projection: The company projects a non-GAAP net loss in the range of $12 million to $14 million for the full year 2025.
Operational Efficiency Impact: The company expects quarterly operating losses to further reduce in Q4 2025 as sales volumes grow and efficiency measures take hold.
Cash Flow and Liquidity: Lifeward has sufficient cash to fund operations into Q1 2026 and is evaluating opportunities to support operations and growth plans while implementing cost management initiatives.
Market Expansion: The company is focusing on global expansion, particularly in the European market, which represents about 40% of its global addressable exoskeleton opportunity.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you confirm the number of rental systems and their breakdown between the United States and Germany?
A:There are 33 active rentals, all of them in Germany.
Q:What impact has the collaboration with CorLife had in the third quarter and going forward?
A:The partnership with CorLife has been progressing well, with a growing pipeline each quarter. The company is learning the training processes and marketing efforts to reach patients and is optimistic about future expansion.
Q:What percentage of ReWalk sales revenue comes from Medicare?
A:Approximately 50% of the total revenue for ReWalk products comes from Medicare.
Q:What is the revenue breakdown of ReWalk within the $3.1 million traditional product sales?
A:$2.9 million is related to the ReWalk product, with the remainder attributed to other products.
Q:What have you learned from reviewing the company’s operations, and what changes are needed to reach growth?
A:The fundamentals of the business need to be established, including better visibility into KPIs and data-driven resource deployment. Strategic partnerships and channel management are key for broader patient access and payer policy development. Scaling operations with high quality and good cost of goods sold (COGS) is also essential.
Q:What triggered the increased sales into Medicare in the third quarter, and how sustainable is it?
A:The increase is attributed to a focused sales force divided into capital sales and patient/payer access. Channel management is still in its early stages, and its impact will be reflected in Q1 of next year.
Q:What gives you confidence in achieving the $24 million to $26 million guidance for 2025 despite the required 21% growth?
A:Confidence is based on Q4 being historically the strongest quarter, a strong existing backlog, and a robust pipeline for both AlterG and ReWalk products.
Q:What caused the 15% decline in AlterG sales, and what steps are being taken to stabilize and grow this segment?
A:The decline is due to a lack of focus in the sales team. The company is implementing a dedicated capital sales team for AlterG and a neuro rehab team for ReWalk, particularly in the U.S. Germany continues to perform well in both areas.
Q:How is ReWalk 7 being introduced in Germany, and what is the market opportunity?
A:ReWalk 7 is being introduced with 33 active rental patients, many of whom convert within 3-6 months. Germany has 40% direct coverage and 100% patient access. Expansion outside Germany is planned as payer access improves.
Q:How does the company plan to address financial challenges and ensure a turnaround?
A:The company is focusing on repairing business fundamentals, leveraging innovation, and seeking strategic partnerships. The CEO is optimistic about the turnaround despite acknowledging the challenges.
Q:What updates are there on expanding AlterG into the sports arena?
A:The company has initiated beta programs in the U.S. with a dedicated capital sales team for AlterG and a neuro rehab team for ReWalk. The sports arena will primarily involve self-pay customers, but government and grant support also contribute significantly.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact percentage breakdown of ReWalk sales revenue from Medicare versus other sources, and the response on AlterG's sports arena expansion lacked clarity on timelines and specific strategies.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Adar CFO
Adar Chief
Advantage ReWalk
Almog Adar
Almog result
CFO Almog
CFO today
CMS fee
California manufacturing
Exo suit
Medicare unit
Oramed capital
ReWalk Personal
ReWalk exoskeleton
ReWalk placement
ReWalk product
ReWalk unit
SEC Almog
access distribution
access market
agreement Oramed
amount proceeds
approach access
approval access
assessment direction
backlog basis
basis Medicare
efficiency measure
fundamental
hold
lead process
liquidity
loan
manufacturing facility
opportunity
record
today release
transformation
work
LFWD Transcript
Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript
Unknown5-15
The earnings call reveals mixed signals: declining revenue and gross margin, but with optimistic guidance on revenue recovery and cash flow improvements. The company's strategic initiatives, such as international expansion and new product launches, are promising. However, the absence of forward guidance and unresolved supply chain issues are concerning. The Q&A section highlights management's confidence in overcoming current challenges, yet lacks specific guidance, creating uncertainty. Thus, the stock price is likely to remain stable, with potential for moderate fluctuations as the market digests these mixed signals.
Lifeward Ltd. (LFWD) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call revealed a 14% revenue decline and flat exoskeleton sales, despite increased unit sales. Gross profit improved, but operating expenses and losses remain high. The Q&A section highlighted uncertainties in the company's market strategy and competitive advantage. Positive elements included narrowed net loss and reduced operating cash usage. However, weak financial performance and lack of clear competitive strategy outweigh these positives, leading to a negative sentiment.
Lifeward Ltd. (LFWD) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call highlights operational efficiencies and a strong pipeline, but concerns arise due to increased operating expenses and cash constraints. The Q&A reveals optimism in partnerships and revenue growth, yet lacks clarity on strategic execution. Despite the positive outlook, uncertainties in Medicare reliance and AlterG sales decline temper enthusiasm. The neutral rating reflects mixed signals, with potential growth balanced by financial and operational challenges.
Lifeward Ltd. (LFWD) Q2 2025 Earnings Call Transcript
Unknown8-14
Despite some positive developments, such as operational efficiencies and Medicare revenue growth, the earnings report reflects mixed signals. Revenue decline, increased GAAP operating expenses due to goodwill impairment, and lack of clear guidance on margin improvements counterbalance the positives. The Q&A further highlights concerns about tariff impacts, unclear margin improvements, and lowered guidance despite expected revenue growth. These mixed signals suggest a neutral market reaction.
LFWD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
